Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

The Fibrosis-4 Index (FIB-4) is used to identify adults who don ... In the US, viral HCC has decreased while HCC incidence ...

They selected one random outpatient visit per person from 2007 to 2020, collecting information such as age, sex, race, body ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more than ...

Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH –– ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial in patients with a type of fatty ...

Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...

Altimmune’s lead drug Pemvidutide demonstrates significant progress in obesity and liver health. See why ALT stock is a ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...